Last updated on April 2019

Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction


Brief description of study

The purpose of this study is to determine if treatment with omecamtiv mecarbil/AMG 423 when added to standard of care is well tolerated and superior to placebo in reducing the risk of cardiovascular death or heart failure events in subjects with chronic HFrEF.

Clinical Study Identifier: NCT02929329

Find a site near you

Start Over

Research Site

Chuo-ku, Japan
0.37miles
  Connect »

Research Site

Minato-ku, Japan
3.08miles
  Connect »

Research Site

Bunkyo-ku, Japan
3.54miles
  Connect »

Research Site

Shinjuku-ku, Japan
3.81miles
  Connect »

Research Site

Shinagawa-ku, Japan
5.2miles
  Connect »

Research Site

Meguro-ku, Japan
6.67miles
  Connect »

Research Site

Itabashi-ku, Japan
7.09miles
  Connect »

Research Site

Urayasu-shi, Japan
7.52miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.